Globalization in pharmaceutical supply chains has changed how generic drug manufacturers are operating and competing globally. There has been a marked decrease in the time to market for generic drugs as well as an increase in the availability, variety and number of generic drugs available on the global market. The face of the Canadian generic market has changed rapidly over the last couple of years, marked by mergers and acquisitions. The regulatory framework in Canada remains more focused on ensuring patent safety and product quality within the market, thus hindering the fulfillment of benefits from the globalization of supply chains within Canada.
The Canadian generics market was worth over USD 4 billion in 2016 and is not expected to post significant growth in the coming years. In fact, the market is expected to barely cross a value of USD 5 billion by the end of 2021.
Aruvian Research presents Analyzing Generics Market in Canada 2017 – a comprehensive coverage of the Canadian generic drugs market. Beginning with a sectional description on the global generic industry, the report looks at an overview of the industry, an analysis of the market volume and value, industry segmentation and an industry forecast.
The Generics Industry in Canada is analyzed through an industry overview which spans the data from 2012 till 2021. An analysis of the industry's value and volume data is included along with an industry segmentation by geography. Industry forecast of the industry is also included.
We also include a Porter’s Five Forces analysis of the Canadian Generics Industry.
Analysis of the major industry players in the Canadian generics market are analyzed through an analysis of their business segments, a financial analysis and a SWOT analysis. Players analyzed include Mylan, Lupin Pharma Canada, Sanofi, Teva and others. This concludes this comprehensive research report from Aruvian Research.
This research report helps you get an insider’s look at the Canadian generic industry and helps you understand what the future holds for the industry. Regulatory framework, pricing and reimbursement scenarios, comparison of the Canadian market with its regional counterparts, all these data points makes this report an essential resource for analytical purposes.